SpringerLink
Log in

Anticoagulants in Use

  • Chapter
  • First Online:
Transfusion Practice in Clinical Neurosciences

  • 691 Accesses

Abstract

Anticoagulation plays a critical role in the management of neurologic disorders. Selection of an anticoagulant must consider both drug-specific and patient-specific factors including type of neurologic condition. Hemorrhagic risk attributed to clinical conditions often influence decision to initiate, discontinue, or resume anticoagulation, with careful consideration for timing and duration of anticoagulant. This chapter describes commonly used anticoagulants in neurosciences. Knowledge of drug-specific properties will inform clinicians and guide appropriate application in the neurocritical care setting.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Warfarin [package insert]. Princeton (NJ): Bristol-Myers Squibb Company; 2010.

    Google Scholar 

  2. Hirsh J, Fuster V, Ansell J, Halperin JL. American Heart Association; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003;107(12):1692–711.

    Article  PubMed  Google Scholar 

  3. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329–33.

    Article  CAS  PubMed  Google Scholar 

  4. Nutescu EA, Burnett A, Fanikos J, Spinler S, Wittkowsky A. Pharmacology of anticoagulants used in the treatment of venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):15–31. Erratum in: J Thromb Thrombolysis. 2016 Aug;42(2):296–311.

    Google Scholar 

  5. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators, Singer DE, Hughes RA, Gress DR, Sheehan MA, Oertel LB, Maraventano SW, Blewett DR, Rosner B, Kistler JP. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990 Nov 29;323(22):1505–1511.

    Google Scholar 

  6. Pengo V, Biasiolo A, Pegoraro C. A simple scheme to initiate oral anticoagulant treatment in outpatients with nonrheumatic atrial fibrillation. Am J Cardiol. 2001;88(10):1214–6.

    Article  CAS  PubMed  Google Scholar 

  7. O’Reilly RA, Rytand DA. “Resistance” to warfarin due to unrecognized vitamin K supplementation. N Engl J Med. 1980;303(3):160–1.

    PubMed  Google Scholar 

  8. Weser JK, Sellers E. Drug interactions with coumarin anticoagulants. 2. N Engl J Med. 1971;285(10):547–58.

    Article  CAS  PubMed  Google Scholar 

  9. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol. 2000;12:Suppl F:27F–32F.

    Google Scholar 

  10. Tulinsky A. Molecular interactions of thrombin. Semin Thromb Hemost. 1996;22:117–24.

    Article  CAS  PubMed  Google Scholar 

  11. Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011;72(4):581–92. Erratum in: Br J Clin Pharmacol. 2011 Oct;72(4):718.

    Google Scholar 

  12. Heparin sodium [package insert]. Deerfield (IL): Baxter Healthcare Corporation; 2017.

    Google Scholar 

  13. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990 Aug;86(2):385–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Bjornsson TD, Wolfram KM, Kitchell BB. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther. 1982 Jan;31(1):104–13.

    Article  CAS  PubMed  Google Scholar 

  15. de Swart CA, Nijmeyer B, Roelofs JM, Sixma JJ. Kinetics of intravenously administered heparin in normal humans. Blood. 1982 Dec;60(6):1251–8.

    Article  PubMed  Google Scholar 

  16. Vandiver JW, Vondracek TG. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Pharmacotherapy. 2012 Jun;32(6):546–58.

    Article  CAS  PubMed  Google Scholar 

  17. Francis JL, Groce JB. Challenges in variation and responsiveness of unfractionated heparin. Pharmacotherapy. 2004;24:108S–19S.

    Article  CAS  PubMed  Google Scholar 

  18. Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S–43S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, Cook DJ, Balekian AA, Klein RC, Le H, Schulman S, Murad MH. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e195S–226S.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol. 2000;12(Suppl. F):27F–32.

    PubMed  Google Scholar 

  21. Stringer KA, Lindenfeld J. Hirudins: antithrombin anticoagulants. Ann Pharmacother. 1992;26:1535–40.

    Article  CAS  PubMed  Google Scholar 

  22. Alban S. Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des. 2008;14:1152–75.

    Article  CAS  PubMed  Google Scholar 

  23. Steinmetzer T, Sturzebecher J. From fibrinogen and hirudin to synthetic anticoagulants. Rational design of thrombin inhibitors. Pharm Unserer Zeit. 2004;33:196–205.

    Article  CAS  PubMed  Google Scholar 

  24. Reed MD, Bell D. Clinical pharmacology of bivalirudin. Pharmacotherapy. 2002;22(6 Pt 2):105S–11S.

    Article  CAS  PubMed  Google Scholar 

  25. Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender. Clin Pharmacol Ther. 2002;71:433–9.

    Article  CAS  PubMed  Google Scholar 

  26. Gosselin RC, Dager WE, King JH, Janatpour K, Mahackian K, Larkin EC, Owings JT. Effect of direct thrombin inhibitors, bivalirudin, lepirudin, and argatroban, on prothrombin time and INR values. Am J Clin Pathol. 2004 Apr;121(4):593–9.

    Article  CAS  PubMed  Google Scholar 

  27. Nutescu EA, Shapiro NL, Chevalier A. New anticoagulant agents: direct thrombin inhibitors. Cardiol Clin. 2008;26(169–87):v–vi.

    Google Scholar 

  28. Arpino PA, Demirjian Z, Van Cott EM. Use of the chromogenic factor x assay to predict the international normalized ratio in patients transitioning from argatroban to warfarin. Pharmacotherapy. 2005;25(2):157–64.

    Article  CAS  PubMed  Google Scholar 

  29. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36:386–99.

    Article  CAS  PubMed  Google Scholar 

  30. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47:285–95.

    Article  CAS  PubMed  Google Scholar 

  31. Stangier J, Stahle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47:47–59.

    Article  CAS  PubMed  Google Scholar 

  32. Eriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development. Clin Pharmacokinet. 2009;48:1–22.

    Article  CAS  PubMed  Google Scholar 

  33. Dabigatran [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals; 2020.

    Google Scholar 

  34. Van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103:1116–27.

    Article  PubMed  Google Scholar 

  35. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981–92.

    Article  CAS  PubMed  Google Scholar 

  36. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369(22):2093–104.

    Article  CAS  PubMed  Google Scholar 

  37. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, Investigators ROCKETAF. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883–91.

    Article  CAS  PubMed  Google Scholar 

  38. Warkentin TE, Pai M, Linkins LA. Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review. Blood. 2017;130(9):1104–13.

    Article  CAS  PubMed  Google Scholar 

  39. Apixaban [package insert]. Princeton (NJ): Bristol-Myers Squibb; 2019.

    Google Scholar 

  40. Chang M, Yu Z, Shenker A, Wang J, Pursley J, Byon W, Boyd RA, LaCreta F, Frost CE. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016;56(5):637–45.

    Article  CAS  PubMed  Google Scholar 

  41. Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, Song Y, Pursley J, Boyd RA, Frost C. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56(5):628–36.

    Article  CAS  PubMed  Google Scholar 

  42. Sarratt SC, Nesbit R, Moye R. Safety outcomes of apixaban compared with warfarin in patients with end-stage renal disease. Ann Pharmacother. 2017;51(6):445–50.

    Article  CAS  PubMed  Google Scholar 

  43. Stanifer JW, Pokorney SD, Chertow GM, Hohnloser SH, Wojdyla DM, Garonzik S, Byon W, Hijazi Z, Lopes RD, Alexander JH, Wallentin L, Granger CB. Apixaban versus warfarin in patients with atrial fibrillation and advanced chronic kidney disease. Circulation. 2020;141(17):1384–92.

    Article  CAS  PubMed  Google Scholar 

  44. Edoxaban [package insert]. Parsippany (NJ): Daiichi Sankyo Co; 2015.

    Google Scholar 

  45. Rivaroxaban [package insert]. Titusville (NH): Janssen Pharmaceuticals; 2020.

    Google Scholar 

  46. Chan KE, Edelman ER, Wenger JB, Thadhani RI, Maddux FW. Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. Circulation. 2015;131(11):972–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Fondaparinux [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2009.

    Google Scholar 

  48. Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, Wex A, Mustafa RA, Morgan RL, Santesso N. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018;2(22):3360–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, Madlener K, Pötzsch B, Klamroth R, Hankowitz J, Banik N, Eberle S, Müller MM, Kropff S, Lindhoff-Last E. Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia. J Am Coll Cardiol. 2017;70(21):2636–48.

    Article  CAS  PubMed  Google Scholar 

  50. Warkentin TE, Maurer BT, Aster RH. Heparin-induced thrombocytopenia associated with fondaparinux. N Engl J Med 2007 June 21;356(25):2653–5; discussion 2653-5.

    Google Scholar 

  51. Mismetti P, Samama CM, Rosencher N, Vielpeau C, Nguyen P, Deygas B, Presles E, Laporte S, PROPICE Study Group. Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study. Thromb Haemost. 2012;107(6):1151–60.

    Article  CAS  PubMed  Google Scholar 

  52. Turpie AG, Lensing AW, Fuji T, Boyle DA. Pharmacokinetic and clinical data supporting the use of fondaparinux 1.5 mg once daily in the prevention of venous thromboembolism in renally impaired patients. Blood Coagul Fibrinolysis. 2009;20(2):114–21.

    Article  CAS  PubMed  Google Scholar 

  53. Zufferey PJ, Ollier E, Delavenne X, Laporte S, Mismetti P, Duffull SB. Incidence and risk factors of major bleeding following major orthopaedic surgery with fondaparinux thromboprophylaxis. A time-to-event analysis. Br J Clin Pharmacol. 2018;84(10):2242–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Dalteparin [package insert]. New York (NY): Pfizer; 2019.

    Google Scholar 

  55. Antman EM, Handin R. Low-molecular-weight heparins: an intriguing new twist with profound implications. Circulation. 1998;98(4):287–9.

    Article  CAS  PubMed  Google Scholar 

  56. Schmid P, Brodmann D, Odermatt Y, Fischer AG, Wuillemin WA. Study of bioaccumulation of dalteparin at a therapeutic dose in patients with renal insufficiency. J Thromb Haemost. 2009;7(10):1629–32.

    Article  CAS  PubMed  Google Scholar 

  57. Pai M, Adhikari NKJ, Ostermann M, Heels-Ansdell D, Douketis JD, Skrobik Y, Qushmaq I, Meade M, Guyatt G, Geerts W, Walsh MW, Crowther MA, Friedrich JO, Burry L, Bellomo R, Brandão da Silva N, Costa Filho R, Cox MJ, Alves Silva S, Cook DJ, PROTECT (Prophylaxis for Thromboembolism in Critical Care Trial) Investigators. Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: a subgroup analysis of the PROTECT trial. PLoS One 2018;13(6):e0198285.

    Google Scholar 

  58. Nishimura RA, Otto CM, Bonow RO, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation. 2014;129(23):2440–92.

    Article  PubMed  Google Scholar 

  59. Bates SM, Greer IA, Middeldorp S, Veenstra DL, Prabulos AM, Vandvik PO. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2)(suppl):e691S–e736S.

    Google Scholar 

  60. Enoxaparin [package insert]. Bridgewater (NJ): Sanofi-Aventis; 2020.

    Google Scholar 

  61. Nyquist P, et al. Prophylaxis of venous thrombosis in neurocritical care patients: an evidence-based guideline: a statement for healthcare professionals from the neurocritical care society. Neurocrit Care. 2016;24(1):47–60.

    Article  PubMed  CAS  Google Scholar 

  62. Sherman DG, Albers GW, Bladin C, Fieschi C, Gabbai AA, Kase CS, O’Riordan W, Pineo GF. The efficacy and safety of enoxaparin versus unfractionated heparin for the prevention of venous thromboembolism after acute ischaemic stroke (PREVAIL study): an open-label randomized comparison. Lancet. 2007;369:1347–55.

    Article  CAS  PubMed  Google Scholar 

  63. Muir KW. The PREVAIL trial and low-molecular-weight heparin for prevention of venous thromboembolism. Stroke. 2008;39:2174–76.

    Google Scholar 

  64. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, Jauch EC, Kidwell CS, Leslie-Mazwi TM, Ovbiagele B, Scott PA, Sheth KN, Southerland AM, Summers DV, Tirschwell DL. American Heart Association Stroke Council. 2018 Guidelines for the early management of patients with Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2018;49(3):e46–e110.

    Article  PubMed  Google Scholar 

  65. Seiffge DJ, Werring DJ, Paciaroni M, Dawson J, Warach S, Milling TJ, Engelter ST, Fischer U, Norrving B. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019;18(1):117–26.

    Article  PubMed  Google Scholar 

  66. Serkin Z, Le S, Sila C. Treatment of extracranial arterial dissection: the roles of antiplatelet agents, anticoagulants, and stenting. Curr Treat Options Neurol. 2019;21(10):48.

    Article  PubMed  Google Scholar 

  67. Lansberg MG, O'Donnell MJ, Khatri P, Lang ES, Nguyen-Huynh MN, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Am Coll Chest Phys Chest. 2012;141(2 Suppl):e601S.

    CAS  Google Scholar 

  68. Toth C, Voll C. Validation of a weight-based nomogram for the use of intravenous heparin in transient ischemic attack or stroke. Clin Trial. 2002;33(3):670–4.

    Google Scholar 

  69. de Bruijn SF, Stam J. Randomized, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis. Stroke. 1999;30(3):484.

    Article  PubMed  Google Scholar 

  70. Benamer HT, Bone I. Cerebral venous thrombosis: anticoagulants or thrombolytic therapy? J Neurol Neurosurg Psychiatry. 2000;69(4):427.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Ferro JM, Bousser MG, Canhão P, Coutinho JM, Crassard I, Dentali F, di Minno M, Maino A, Martinelli I, Masuhr F, Aguiar de Sousa D, Stam J. European stroke organization. European stroke organization guideline for the diagnosis and treatment of cerebral venous thrombosis - endorsed by the European Academy of Neurology. Eur J Neurol. 2017;24(10):1203.

    Article  CAS  PubMed  Google Scholar 

  72. Misra UK, Kalita J, Chandra S, Kumar B, Bansal V. Low molecular weight heparin versus unfractionated heparin in cerebral venous sinus thrombosis: a randomized controlled trial. Eur J Neurol. 2012;19:1030–6.

    Article  CAS  PubMed  Google Scholar 

  73. Schulman S, Crowther MA. How I treat with anticoagulants in 2012: new and old anticoagulants, and when and how to switch. Blood. 2012;119:3016–23.

    Article  CAS  PubMed  Google Scholar 

  74. Whitlock RP, Fordyce CB, Midei MG, Ellis D, Garcia D, Weitz JI, Canafax DM, Albrecht D, Milner PG. A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The Embrace AC trial. Thromb Haemost. 2016;116(2):241–50.

    PubMed  Google Scholar 

  75. Bavisotto LM, Ellis DJ, Milner PG, Combs DL, Irwin I, Canafax DM. Tecarfarin, a novel vitamin K reductase antagonist, is not affected by CYP2C9 and CYP3A4 inhibition following concomitant administration of fluconazole in healthy participants. J Clin Pharmacol. 2011;51(4):561–74.

    Article  CAS  PubMed  Google Scholar 

  76. Clinical trial number NCT02522221 for “Tecarfarin Anti-Coagulation Trial (TACT)” at ClinicalTrials.gov.

  77. Fuentes-Prior P, Iwanaga Y, Huber R, et al. Structural basis for the anticoagulant activity of the thrombin-thrombomodulin complex. Nature. 2000;404(6777):518–25.

    Article  CAS  PubMed  Google Scholar 

  78. Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol. 2012;34(1):107–25.

    Article  CAS  PubMed  Google Scholar 

  79. Yamakawa K, Murao S, Aihara M. Recombinant human soluble thrombomodulin in sepsis-induced coagulopathy: an updated systematic review and meta-analysis. Thromb Haemost. 2019;119(1):56–65.

    Article  PubMed  Google Scholar 

  80. Kearon C, Comp P, Douketis J, Royds R, Yamada K, Gent M. Dose-response study of recombinant human soluble thrombomodulin (ART-123) in the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2005;3(5):962–8.

    Article  CAS  PubMed  Google Scholar 

  81. Iba T, Thachil J. Present and future of anticoagulant therapy using antithrombin and thrombomodulin for sepsis-associated disseminated intravascular coagulation: a perspective from Japan. Int J Hematol. 2016;103(3):253–61.

    Article  CAS  PubMed  Google Scholar 

  82. Verhamme P, Pakola S, Jensen TJ. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers. Clin Ther. 2010;32:1205–20.

    Article  CAS  PubMed  Google Scholar 

  83. Verhamme P, Tangelder M, Verhaeghe R, et al. Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial. J Thromb Haemost. 2011;09:664–71.

    Article  CAS  Google Scholar 

  84. Verhamme P, Gunn S, Sonesson E, Peerlinck K, Vanassche T, Vandenbriele C, Ageno W, Glazer S, Prins M, Buller H, Tangelder M. Single-dose TB-402 or rivaroxaban for the prevention of venous thromboembolism after total hip replacement. A randomised, controlled trial. Thromb Haemost. 2013 Jun;109(6):1091–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Yale New Haven Hospital, New Haven, CT, USA

    Albert C. Zichichi, Abdalla A. Ammar, Mahmoud A. Ammar, Nicholas A. DeFilippo & Kent A. Owusu

  2. School of Pharmacy, University of Connecticut, Storrs, CT, USA

    Nicholas A. DeFilippo

  3. Care Signature, Yale New Haven Health, New Haven, CT, USA

    Kent A. Owusu

Authors
  1. Albert C. Zichichi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abdalla A. Ammar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mahmoud A. Ammar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nicholas A. DeFilippo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kent A. Owusu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kent A. Owusu .

Editor information

Editors and Affiliations

  1. Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Hemanshu Prabhakar

  2. Anesthesiology and Intensive Care, G B Pant Institute of Medical Education and Research, New Delhi, Delhi, India

    Monica S Tandon

  3. Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Indu Kapoor

  4. Neuroanaesthesiology and Critical Care, All India Institute of Medical Sciences, New Delhi, Delhi, India

    Charu Mahajan

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Zichichi, A.C., Ammar, A.A., Ammar, M.A., DeFilippo, N.A., Owusu, K.A. (2022). Anticoagulants in Use. In: Prabhakar, H., S Tandon, M., Kapoor, I., Mahajan, C. (eds) Transfusion Practice in Clinical Neurosciences. Springer, Singapore. https://doi.org/10.1007/978-981-19-0954-2_32

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-0954-2_32

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-0953-5

  • Online ISBN: 978-981-19-0954-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation